Translations:Resveratrol/39/en

Reported resveratrol plasma concentration in humans after repeated doses of resveratrol (studies after 2010). ^[1]
Number of Participants, Characteristics, Study Type	Dose (mg/day)	Days	Administration	Peak Plasma Concentration (ng/mL)
6, low BMI	2125	11	Tablet and drink	903.0
6, high BMI	2125	11	Tablet and drink	245.0
35, healthy males, cross-over study	800	5	Capsule	0.56
			Dairy drink	0.61
			Soy drink	0.58
			Protein-free drink	0.70
7, healthy	500	28	Capsule with Piperine	2967.25
40, healthy, repeated sequential dosing	500	29	Caplet	43.8
	1000			141
	2500			331
	5000			967
6, patients with hepatic metastases, randomized double-blind clinical trial	5000	14	Micronized resveratrol mixed in liquid	1942
8, healthy subjects	2000	7	Capsule	1274
19, overweight or obese, randomized, double-blind, placebo-controlled, crossover intervention	30	6	Capsule	181.31
	90			532.00
	270			1232.16

↑ Springer M & Moco S: Resveratrol and Its Human Metabolites-Effects on Metabolic Health and Obesity. Nutrients 2019. (PMID 30641865) [PubMed] [DOI] [Full text] Resveratrol is one of the most widely studied polyphenols and it has been assigned a plethora of metabolic effects with potential health benefits. Given its low bioavailability and extensive metabolism, clinical studies using resveratrol have not always replicated in vitro observations. In this review, we discuss human metabolism and biotransformation of resveratrol, and reported molecular mechanisms of action, within the context of metabolic health and obesity. Resveratrol has been described as mimicking caloric restriction, leading to improved exercise performance and insulin sensitivity (increasing energy expenditure), as well as having a body fat-lowering effect by inhibiting adipogenesis, and increasing lipid mobilization in adipose tissue. These multi-organ effects place resveratrol as an anti-obesity bioactive of potential therapeutic use.